Therefore, in the future, a larger prospective study with solid outcomes (atherosclerotic cardiovascular diseases or all-cause or cardiovascular mortality) analyzing HDL-subclasses [45] might be useful to assess adiponectin’s role as a biomarker for metabolic or atherosclerotic cardiovascular diseases. This evidence concerns the gene ADIPOQ and cardiovascular disorder.